Larimar Therapeutics/LRMR

$11.74

-5.24%
-
1D1W1MYTD1YMAX

About Larimar Therapeutics

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases using its cell penetrating peptide (CPP) technology platform. The Company’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreichs ataxia (FA). CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with FA. FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient frataxin (FXN) due to a genetic abnormality. It also focuses on using its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. Its CPP platform enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets.

Ticker

LRMR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Carole Ben-Maimon

Employees

26

Headquarters

Bala cynwyd, United States

LRMR Metrics

BasicAdvanced
$740.15M
Market cap
-
P/E ratio
-$0.76
EPS
0.97
Beta
-
Dividend rate

What the Analysts think about LRMR

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
57.58% upside
High $25.00
Low $10.00
$11.74
Current price
$18.50
Average price target

LRMR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-9M
8.43%
Profit margin
0%
-

LRMR Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.21
-$0.15
-$0.19
-$0.21
-
Expected
-$0.27
-$0.25
-$0.20
-$0.22
-$0.25
Surprise
-22.94%
-39.02%
-2.56%
-6%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Larimar Therapeutics stock

Buy or sell Larimar Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing